Investigating the role of specific proteins in the development of harmful immune cells linked to autoimmune diseases.
Role of Class IIa HDACs HDAC4 and HDAC7 in Pathogenic Th17 Cell Development and Colitis
This study is looking at how specific proteins affect the growth of immune cells that can cause autoimmune diseases like colitis, multiple sclerosis, and rheumatoid arthritis, with the hope of finding new ways to treat these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11009049 on NIH RePORTER |
What this research studies
This research focuses on understanding how certain proteins, known as Class IIa HDACs (specifically HDAC4 and HDAC7), influence the development of Th17 cells, which are immune cells involved in autoimmune diseases like colitis, multiple sclerosis, and rheumatoid arthritis. By examining the genetic and molecular mechanisms that regulate these cells, the study aims to uncover how their dysregulation contributes to inflammation and disease. Patients may benefit from insights gained that could lead to new therapeutic strategies targeting these pathways.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with autoimmune diseases such as inflammatory bowel disease, multiple sclerosis, or rheumatoid arthritis.
Not a fit: Patients with non-autoimmune conditions or those not affected by Th17 cell dysregulation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for autoimmune diseases by targeting the mechanisms that drive harmful immune responses.
How similar studies have performed: Previous research has shown promising results in understanding Th17 cell regulation, indicating that this approach could yield valuable insights.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Cheung, Kalung — Icahn School of Medicine at Mount Sinai
- Study coordinator: Cheung, Kalung
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.